SCHEMBL6476791

SCHEMBL6476791

CCOC(=O)C(Cc1ccc(OCCn2c(=O)oc3ccccc32)cc1)C(=O)OCC

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.58
ALDH1A1 P00352 3/20 0.55
HPGD P15428 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
MAPT P10636 1/20 0.55
TP53 P04637 1/20 0.55
POLB P06746 4/20 0.54
HTT P42858 2/20 0.54
LMNA P02545 1/20 0.54
GAA P10253 1/20 0.54
TSHR P16473 3/20 0.54
RAB9A P51151 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
KMT2A Q03164 2/20 0.50
PPARG P37231 1/20 0.49
PPARD Q03181 1/20 0.49
PPARA Q07869 1/20 0.49
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475653 0.96 L3MBTL1 (0.56) L3MBTL1ALDH1A1HPGDNPSR1MAPT
SCHEMBL6477400 0.88 TSHR (0.62) L3MBTL1ALDH1A1HPGDNPSR1MAPT
SCHEMBL6476905 0.80 TSHR (0.62) L3MBTL1ALDH1A1HPGDNPSR1MAPT
SCHEMBL6476253 0.80 NPC1 (0.65) L3MBTL1ALDH1A1HPGDTP53LMNA
SCHEMBL6476013 0.79 PPARG (0.56) L3MBTL1ALDH1A1HPGDNPSR1MAPT
SCHEMBL6475863 0.79 L3MBTL1 (0.57) L3MBTL1ALDH1A1HPGDNPSR1MAPT
SCHEMBL6483665 0.78 PPARG (0.70) L3MBTL1ALDH1A1HPGDNPSR1MAPT
SCHEMBL6485878 0.77 PPARG (0.53) L3MBTL1ALDH1A1HPGDNPSR1MAPT
SCHEMBL6476311 0.77 SIGMAR1 (0.53) L3MBTL1ALDH1A1HPGDNPSR1MAPT
SCHEMBL6476696 0.76 PPARG (0.48) ALDH1A1HPGDNPSR1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1252150-B1 HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2003-06-04 EP claimed
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2003-02-27 US claimed
US-6919362-B2 Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2005-07-19 US disclosed
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2003-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same CYP2F1, CYP11B2, CYP4B1 L3MBTL1 4870/4885ALDH1A1 687/4885HPGD 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.